Caris Life Sciences, Inc. (CAI Proposed), a cancer-focused precision medicine pioneer, revealed its IPO terms – 23.53 million shares at a price range of $16.00 to $18.00 – to raise $400.0 million, if priced at the $17.00 mid-point of its range – in an S-1/A filing early today, Monday, June 9, 2025. At pricing, Caris Life Sciences would have a market cap of about $5.05 billion – assuming mid-point pricing at $17.00.
Bankers expect to price Caris Life Sciences’ IPO next week. This is a NASDAQ listing. (Please see our IPO Calendar for the details.)
BofA Securities, J.P.Morgan and Goldman Sachs are the lead joint book-runners.
Caris Life Sciences, founded in 2008 and based in Irving, Texas, describes itself as “a leading patient-centric, next-generation AI TechBio company and precision medicine pioneer,” according to the prospectus.
“We have spent the last 17 years developing and building our portfolio of comprehensive, proprietary molecular profiling solutions and generating what we believe to be one of the largest and most comprehensive multi-modal clinico-genomic datasets in oncology based on the more than 6.5 million tests we have run on over 849,000 cases, which have generated measurements of over 38 billion molecular markers,” Caris Life Sciences said in the prospectus.
Caris Life Sciences is not profitable, according to the financial statements in the prospectus: Net loss of $248.7 million on revenue of $452.5 million for the 12 months that ended March 31, 2025.
(For more information about these companies, please check the IPO Calendar and the individual IPO Profiles found on the IPOScoop.com website.)
Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.
To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.
Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.
Disclaimer: A SCOOP Rating (Wall Street Consensus of Opening-day Premiums) is a general consensus taken, at press time, from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading. The SCOOP Rating does not reflect the opinions of anyone associated with IPOScoop.com. The SCOOP ratings should not be taken as investment advice. The rating merely reflects the opinion of the professionals at the time of publication and is subject to last-minute changes due to market conditions, changes in a specific offering and other factors, such as changes in the proposed offering terms and the shifting of investor interest in the IPO. The information offered is taken from sources we believe to be reliable, but we cannot guarantee the accuracy.